Best Of
Re: How has normal, day-to-day life changed for you after diagnosis? Share your “different normal.”
This site needs more promotion. So much traffic was lost when the site was updated. Covid might have been what had so many join and post. I know the need for this site is important.
Re: Starting chemo in October 2025? Let's support each other here!
Hi Everyone, This is a quiet group so I hope it means you’re all weathering chemo ok. In case my experience is helpful for anyone, my 2nd infusion was a similar experience to the first. In both I used ice packs on my hands and feet. They were really very cold and eventually got a little painful so I had to take them off about half way to give me a chance to warm up a bit before putting them back on. So far I have not had any neuropathy. (I did not elect to use cold caps, and predictably lost my hair.) I have had some weird sandpaper-y feeling in my mouth and tongue about a week after infusion (which is going away) and definitely a blunted sense of taste, that has persisted. Food enjoyment is not the same but I haven’t had any nausea. Being able to get a good night’s sleep makes a huge difference in how I feel. My energy is slowly coming back and hoping this is the case for the last week+ before my next infusion. I hope someone can share whether their infusions seemed to all be similar side effects or if some side effects accumulated/ got worse towards the end. Hang in there everyone! I wish you the best with your treatments and recoveries.
Re: Older Women Treated With Hormone Therapy May Not Need Radiation
Hi Elem:
With hormone receptor-positive disease (ER+ and/or PR+), when you meet with the medical oncologist, you will probably discuss "endocrine therapy" (e.g., tamoxifen or an aromatase inhibitor ("AI")). These drugs are in "pill" form.
Be sure to ask the medical oncologist about the HER2 status. HER2-positive disease is treated quite differently from HER2-negative disease, so this result is critical information with respect to chemotherapy and HER2-targeted therapy.
If you have not already done so, be sure to obtain copies of the pathology reports from all biopsies and surgeries, along with any addenda or supplements with ER, PR and HER2 test results for your review and records. It is best practice to confirm the information you receive with the underlying documents (with your name and actual results).
As far as radiation and the original post in this thread, I think that this is the related news feature (dated May 18, 2015). The Moderators should have included a link to it in their post.
Feature: http://www.breastcancer.org/research-news/some-treated-w-hormonal-tx-may-not-need-rads
Liu (2015) Study Publication: http://ascopubs.org/doi/full/10.1200/JCO.2014.57.7999
Bellon (2015) comment: http://ascopubs.org/doi/full/10.1200/JCO.2015.61.2069
The title of the feature is rather misleading, and the study had significant limitations. As a result, this study was not seen as a practice changing study. Further research to substantiate or validate the findings is needed before it is implemented in the clinic, as noted by the authors:
"However, omitting RT and using intrinsic subtyping and clinical factors is a substantial change in care. The breast cancer community would likely require additional prospective evidence before this becomes standard of practice. To validate this observation, a prospective, single-arm clinical trial open to women age 55 years or older with pT1N0 grade 1 to 2 luminal A breast cancer has begun in Canada. . .
. . .Further studies may validate the exploratory finding of a low-risk group of postmenopausal women with early-stage luminal A breast cancer group who may be spared the inconvenience and adverse effects of breast RT."
Other clinical trials regarding the omission of radiation therapy in older patients have used higher age cut-offs (e.g., PRIME II, age 65 or older; CALGB 9343, ≥ 70 years).
As of this date, the National Comprehensive Cancer Network (NCCN) guidelines (Version 2.2016) provide that breast radiation therapy may be omitted in select patients ≥70 y of age with estrogen-receptor positive, clinically node-negative, T1 tumors who receive adjuvant endocrine therapy (category 1). Patients should seek case-specific, expert professional advice from a Radiation Oncologist to understand whether this is a reasonable option for them.
In any event, when you meet with the Radiation Oncologist, do not hesitate to request a personalized risk benefit analysis. Inquire what clinical and pathologic factors weigh in favor of radiation therapy in your specific case. Ask about your estimated risk of local recurrence, and the estimated absolute risk reduction benefit you would receive from any particular course, which must be weighed against the risks. With some lower risk disease, shorter courses may be an option.
BarredOwl
Re: Can we have a forum for "older" people with bc?
Teka, it is a tie!! We also had snow last night.
I haven't gotten much done today. However, it is Sunday.
I left a book-club several years ago because of relationship problems with another member. I had a talk with that person a week ago. I understand my part in the difficulty, and I am interested in returning. I don't know, but something is happening. A wait and see kind of thing.
I am getting a bit more lax with my rehab exercises, but I will still get my five sessions for today. A nap and Mass got things out of kilter for the 10, 12, 2, 4, and 6 schedule. I want to get at least half an hour resting between sessions. Oh, what problems!
Re: Who's starting Radiation in November 2025? Let's gather here to share!
Hi everyone, I am going to be started full breast radiation everyday for 4 weeks and I have some questions. I am hearing difference stories about being able to be around kids during my radiation or having to take time out of work and I didn't know if anyone has gone through the same and knew if any of that is true and maybe help guide me on what to expect.
I do plan on asking my doctor when I see her for my Stem visit on 11/20 but I didn't know if anyone here could help me on what to expect.
Thank you!
